Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti

Molecular Microbiology

Volumn 46, Issue 3, 2002, Pages 709-717

  Pym, Alexander S ^a,b   Brodin, Priscille ^a   Brosch, Roland ^a   Huerre, Michel ^a   Cole, Stewart T ^a  

^a INSTITUT PASTEUR   (France)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; CFP 10 PROTEIN; EARLY SECRETORY ANTIGENIC TARGET 6; LIVE VACCINE; MYCOBACTERIUM VACCINE; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACILLUS; BACTERIAL STRAIN; BCG VACCINATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG SAFETY; GENE LOCUS; GENE STRUCTURE; GENETIC CODE; GENETIC DISORDER; GRANULOMA; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MICROBIAL ATTENUATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POPULATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPECIES; SPLENOMEGALY; SUPERNATANT; T LYMPHOCYTE; VIRULENCE; VOLE;

ANIMALS; ANTIGENS, BACTERIAL; ARVICOLINAE; BACTERIAL PROTEINS; BCG VACCINE; CATTLE; FEMALE; GENE DELETION; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, ATTENUATED; VIRULENCE;

ACTINOBACTERIA (CLASS); ANIMALIA; BACILLI; BACTERIA (MICROORGANISMS); MURIDAE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0036437048     PISSN: 0950382X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2958.2002.03237.x     Document Type: Article

References (45)

1. Bange, W.R., Collins, F.M., and Jacobs, W.R., Jr (1999) Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tubercle Lung Dis 79: 171-180.
2. Banu, S., Honoré, N., Saint-Joanis, B., Philpott, D., Prévost, M.-C., and Cole, S.T. (2002) Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol 44: 9-19.
3. Barry, C.E. (2001) Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. Trends Microbiol 9: 237-241.
4. Beatty, W.L., Ullrich, H.J., and Russell, D.G. (2001) Mycobacterial surface moieties are released from infected macrophages by a constitutive exocytic event. Eur J Cell Biol 80: 31-40.
5. Behr, M.A., Wilson, M.A., Gill, W.P., Salamon, H., Schoolnik, G.K., Rane, S., and Small, P.M. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarrays. Science 284: 1520-1523.
6. Berthet, F.X., Rasmussen, P.B., Rosenkrandt, I., Andersen, P., and Gicquel, B. (1998a) A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144: 3195-3203.
7. Berthet, F.X., Lagranderie, M., Gounon, P., Laurent-Winter, C., Ensergueix, D., Chavarot, P., et al. (1998b) Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 282: 759-762.
8. Bloom, B.R., and Fine, P.E.M. (1994) The BCG experience: Implications for future vaccines against tuberculosis. In Tuberculosis: Pathogenesis, Protection, and Control. Bloom, B.R. (ed.). Washington, DC: American Society for Microbiology Press, pp. 531-557.
9. Bloom, B.R., and Murray, C.J.L. (1992) Tuberculosis: Commentary on a reemergent killer. Science 257: 1055-1064.
10. Brandt, L., Elhay, M., Rosenkrands, I., Lindblad, E.B., and Andersen, P. (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68: 791-795.
11. Brennan, M.J., and Delogu, G. (2002) The PE multigene family: A molecular mantra for mycobacteria. Trends Microbiol 10: 246-249.
12. Brodin, P., Eiglmeier, K., Marmiesse, M., Billault, A., Garnier, T., Niemann, S., et al. (2002) Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. Infect Immun 70: 5568-5578.
13. Brosch, R., Gordon, S.V., Billault, A., Garnier, T., Eiglmeier, K., Soravito, C., et al. (1998) Use of a Mycobacterium tuberculosis H37Rv bacterial artificial chromosome (BAC) library for genome mapping, sequencing and comparative genomics. Infect Immun 66: 2221-2229.
14. Brosch, R., Gordon, S.V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., et al. (2002) A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 99: 3684-3689.
15. Calmette, A. (1927) In La Vaccination Preventive Contre la Tuberculose. Paris: Masson et cie, pp. 250.
16. Calmette, A., and Guérin, C. (1911) Recherches expérimentales sur la défense de l'organisme contre l'infection tuberculeuse. Ann Inst Pasteur 25: 625-641.
17. Colangelli, R., Spencer, J.S., Bifani, P., Williams, A., Lyaschenko, K., Keen, M.A., et al. (2000) MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs. Infect Immun 68: 990-993.
18. Cole, S.T. (1998) Comparative mycobacterial genomics. Curr Opin Microbiol 1: 567-571.
19. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
20. Fine, P.E.M. (1995) Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 346: 1339-1345.
21. Glickman, M.S., Cox, J.S., and Jacobs, W.R., Jr (2000) A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5: 717-727.
22. Gordon, S.V., Brosch, R., Billault, A., Garnier, T., Eiglmeier, K., and Cole, S.T. (1999) Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32: 643-656.
23. Harboe, M., Malin, A.S., Dockrell, H.S., Wiker, H.G., Ulvund, G., Holm, A., et al. (1998) B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect Immun 66: 717-723.
24. Hart, P.D., and Sutherland, I. (1977) BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 2(6082): 293-295.
25. Horwitz, M.A., Harth, G., Dillon, B.J., and Maslesa-Galic, S. (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97: 13853-13858.
26. Lee, M.H., Pascopella, L., Jacobs, W.R., and Hatfull, G.F. (1991) Site-specific integration of mycobacteriophage L5: Integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin. Proc Natl Acad Sci USA 88: 3111-3115.
27. Louise, R., Skjot, V., Agger, E.M., and Andersen, P. (2001) Antigen discovery and tuberculosis vaccine development in the post-genomic era. Scand J Infect Dis 33: 643-647.
28. Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C., and Stover, C.K. (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274-1282.
29. Mollenkopf, H.J., Groine-Triebkorn, D., Andersen, P., Hess, J., and Kaufmann, S.H. (2001) Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine 19: 4028-4035.
30. Murray, P.J., Aldovini, A., and Young, R.A. (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 93: 934-939.
31. Oettinger, T., Jorgensen, M., Ladefoged, A., Haslov, K., and Andersen, P. (1999) Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogical tree. Tubercle Lung Dis 79: 243-250.
32. Olsen, A.W., Hansen, P.R., Holm, A., and Andersen, P. (2000) Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30: 1724-1732.
33. Ponnighaus, J.M., Fine, P.E., Sterne, J.A., Wilson, R.J., Msosa, E., Gruer, P.J., et al. (1992) Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339: 636-639.
34. Pym, A.S., Domenech, P., Honoré, N., Song, J., Deretic, V., and Cole, S.T. (2001) Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol 40: 879-889.
35. Renshaw, P.S., Panagiotidou, P., Whelan, A., Gordon, S.V., Hewinson, G.R., Williamson, R.A., and Carr, M.D. (2002) Conclusive evidence that the major T-cell antigens of the M. tuberculosis complex ESAT-6 and CFP-10 form a tight, 1: 1 complex and characterisation of the structural properties of ESAT-6, CFP-10 and the ESAT-6-CFP-10 complex: Implications for pathogenesis and virulence. J Biol Chem 274: 21598-21603.
36. Salamon, H., Kato-Maeda, M., Small, P.M., Drenkow, J., and Gingeras, T.R. (2000) Detection of deleted genomic DNA using a semiautomated computational analysis of Gene-Chip data. Genome Res 10: 2044-2054.
37. Sampson, S.L., Lukey, P., Warren, R.M., van Helden, P.D., Richardson, M., and Everett, M.J. (2001) Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917c. Tuberculosis (Edinb) 81: 305-317.
38. Skjøt, R.L.V., Oettinger, T., Rosenkrands, I., Ravn, P., Brock, I., Jacobsen, S., and Andersen, P. (2000) Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68: 214-220.
39. Sorensen, A.L., Nagai, S., Houen, G., Andersen, P., and Andersen, Å. (1995) Purification and characterization of a low molecular mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63: 1710-1717.
40. Spencer, J.S., Marques, M.A., Lima, M.C., Junqueira-Kipnis, A.P., Gregory, B.C., Truman, R.W., and Brennan, P.J. (2002) Antigenic specificity of the Mycobacterium leprae homologue of ESAT-6. Infect Immun 70: 1010-1013.
41. Sula, L., and Radkovsky, J. (1976) Protective effects of M. microti vaccine against tuberculosis. J Hyg Epidemiol Microbiol Immunol 20: 1-6.
42. Tekaia, F., Gordon, S.V., Garnier, T., Brosch, R., Barrell, B.G., and Cole, S.T. (1999) Analysis of the proteome of Mycobacterium tuberculosis in silico. Tubercle Lung Dis 79: 329-342.
43. Tuberculosis Prevention Trial, Madras (1980) Trial of BCG vaccines in South India for tuberculosis prevention. Ind J Med Res 72 (Suppl.): 1-74.
44. Wards, B.J., de Lisle, G.W., and Collins, D.M. (2000) An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine. Tubercle Lung Dis 80: 185-189.
45. Wells, A.Q. (1937) Tuberculosis in wild voles. Lancet 232: 1221.